**Modeling Developmental and Tumorigenic Aspects of Trilateral Retinoblastoma via Human Embryonic Stem Cells**

Yishai Avior, Elyad Lezmi, Dorit Yanuka, and Nissim Benvenisty

1The Azrieli Center for Stem Cells and Genetic Research, Institute of Life Sciences, The Hebrew University of Jerusalem, Givat-Ram, Jerusalem 91904, Israel

*Correspondence: nissimb@mail.huji.ac.il

http://dx.doi.org/10.1016/j.stemcr.2017.03.005

**SUMMARY**

Human embryonic stem cells (hESCs) provide a platform for studying human development and understanding mechanisms underlying diseases. Retinoblastoma-1 (RB1) is a key regulator of cell cycling, of which biallelic inactivation initiates retinoblastoma, the most common congenital intraocular malignancy. We developed a model to study the role of RB1 in early development and tumor formation by generating RB1-null hESCs using CRISPR/Cas9. RB1−/− hESCs initiated extremely large teratomas, with neural expansions similar to those of trilateral retinoblastoma tumors, in which retinoblastoma is accompanied by intracranial neural tumors. Teratoma analysis further revealed a role for the transcription factor ZEB1 in RB1-mediated ectoderm differentiation. Furthermore, RB1−/− cells displayed mitochondrial dysfunction similar to poorly differentiated retinoblastomas. Screening more than 100 chemotherapies revealed an RB1−/−-specific cell sensitivity to carboplatin, exploiting their mitochondrial dysfunction. Together, our work provides a human pluripotent cell model for retinoblastoma and sheds light on developmental and tumorigenic roles of RB1.

**RESULTS**

We used the CRISPR/Cas9 gene-editing approach to generate hESCs with mutations in RB1. Karyotypically
normal hESCs were transfected either with the Cas9 gene along a guide RNA targeting the first exon of the RB1 gene (blue and green). Control A is the untreated cell line, and control B underwent the same transfection with a Cas9 vector without a guide sequence.

(B) Western blot analysis for pRB shows ablated protein expression in biallelic mutations in RB1.

(C) Relative gene expression of RB1 homologs, RBL1 and RBL2, in control and RB1−/− hESCs. Error bars represent SEM. *p < 0.05 (calculated using Student’s t test).

(D) Heatmap of RB1 cofactors and gene target expression. Two independent control cell lines and three mutant ones are shown. See also Figure S1.

Figure 1. Generation and Characterization of RB1−/− hESCs

(A) DNA sequencing of control and mutant clones following CRISPR/Cas9 and a guide sequence targeting the first exon of the RB1 gene (blue and green). Control A is the untreated cell line, and control B underwent the same transfection with a Cas9 vector without a guide sequence.

(B) Western blot analysis for pRB shows ablated protein expression in biallelic mutations in RB1.

(C) Relative gene expression of RB1 homologs, RBL1 and RBL2, in control and RB1−/− hESCs. Error bars represent SEM. *p < 0.05 (calculated using Student’s t test).

(D) Heatmap of RB1 cofactors and gene target expression. Two independent control cell lines and three mutant ones are shown. See also Figure S1.
from and malignant processes. Neural progenitor cells derived dance and affects mitochondrial structure and function. Thus, different assays were used to address these possibilities. mtDNA abundance was evaluated by calculating the ratio between mitochondrial and nuclear DNA, revealing an average depletion of 45% ± 8% (p < 0.001) in mtDNA in RB1−/− clones (Figure 2B). Mitochondrial function was quantified using a live-cell metabolic assay with an Agilent Seahorse analyzer. RB1−/− cells showed a 51% ± 7% (p < 0.001) decrease in basal respiration and a 69% ± 7% (p < 0.001) reduction in ATP production (the product of oxidative phosphorylation) compared with control cells. Furthermore, the maximal respiration rate of mutant cells was similarly reduced, resulting in cells respiring close to their maximal respiratory capacity (Figures 2C, S2A, and S2B). The mitochondrial respiration decrease was concomitant with a 65% ± 15% (p < 0.001) increase in basal cellular glycolysis and a 45% ± 7% (p < 0.01) increase following disruption of ATP synthesis (Figures 2C, S2A, and S2B). Calculation of glycolytic rate using a designated formula (Mookerjee et al., 2016) emphasized these differences, with mutant cells exhibiting an approximately 2-fold higher rate compared with controls (550 ± 54 and 269 ± 35 pmol H+/min/μg protein, respectively). Together, these data suggested that RB1−/− hESCs harbor a decrease in mitochondrial activity and an increase in glycolytic rate.

To evaluate any structural basis for the reduced mitochondrial activity, we visualized control and mutant cells using transmission electron microscopy (TEM) (Figures 2D and S2C). Strikingly, RB1−/− clones showed multiple phenotypes of aberrant mitochondria, such as elongated and deformed mitochondria, and ghost mitochondria. Quantification of TEM micrographs revealed a significant downregulation of normal mitochondrial hallmarks including intact outer membrane, defined cristae and adjacent ER, and an increase in mitochondrial malformation (Figure 2E). Interestingly, western blot analysis did not reveal differences between inner and outer mitochondrial membrane protein expression (Figure S2D), suggesting that mitochondrial protein expression was not globally decreased and that the defect in function correlated better with mtDNA copy number (Figure 2B). Together, these data suggest that RB1 ablation in hESCs reduces mtDNA abundance and affects mitochondrial structure and function.

hESC differentiation can shed light on developmental and malignant processes. Neural progenitor cells derived from RB1-null hESCs did not differ significantly from control cells (Figure S3A), suggesting that a more complex differentiation paradigm is required to model pRB’s tumorigenic and developmental roles. We therefore generated teratomas from RB1-null and control cells, allowing us to study the effects of RB1 ablation in vivo. Teratomas derived from RB1−/− hESCs were significantly larger than control tumors (Figures 3A and S3B). Serial sectioning of the teratomas revealed a dramatic expansion of neural structures in tumors derived from RB1−/− clones, visualized by H&E staining and immunofluorescence staining for the specific neuronal marker neural cell adhesion molecule 1 (NCAM1) (Figures 3B and 3C). RNA-seq analysis of the tumors showed a clear separation between expression patterns, with 8.0% (1,545/20,690) of the expressed transcripts at least 3-fold upregulated or downregulated in teratomas derived from RB1−/− clones (Figure S3C). In accordance with the high abundance of neural structures in the RB1−/− tumors, the upregulated genes were significantly enriched for annotations related to the nervous system and neural development (Figure 3D). Downregulated genes were enriched for epidermal related annotations, such as keratinocyte differentiation (Figure 3D). This is intriguing, as both the nervous system and the epidermis are derivatives of the same embryonic germ layer, the ectoderm. To a lesser extent, downregulated genes were enriched for muscle and bone formation categories. Interestingly, both upregulated and downregulated gene groups were enriched for transcripts annotated to include binding sites to the zinc finger E-box binding homeobox 1 (ZEB1) transcription factor (Figure 3E), which is a master regulator of the epithelial-mesenchymal transition (EMT) (Eger et al., 2005). ZEB1 expression was previously shown to be regulated by pRB and E2F (Liu et al., 2007), and was significantly upregulated in RB1−/− teratomas (Figure 3F). Higher ZEB1 expression correlated with epithelial and mesenchymal marker up- and downregulation, respectively (Figure 3G). ZEB1 target genes downregulated in RB1−/− teratomas included epidermal keratins, while upregulated ZEB1 target genes included neural markers such as NCAM1 and NCAM2, and NEUROD4 (Figures 3H and 3I). Furthermore, ZEB1 was previously shown to promote cell proliferation through regulation of genes such as MKI67 and OLG2, whose expression was upregulated in RB1−/− teratomas (Figure 3J). Several E2F genes were also upregulated in the mutant teratomas, correlating with enlarged tumors (Figure S3D). Finally, using immunofluorescence staining we found that ZEB1 expression was localized to the same neural structures enlarged following RB1 mutation, suggesting its involvement in this phenotype (Figure 3K).

Following the characterization of RB1-null cells and their tumorigenic capacities, we utilized them in a drug-screening platform. As TRb patients are commonly treated with chemotherapies aimed at reducing or eliminating tumors (Dunkel et al., 2010; Wright et al., 2010), we used our disease model to analyze the relative potency of a variety of chemotherapy. An initial drug screening of 119 chemotherapies. An initial drug screening of 119
Figure 2. RB1−/− hESC Aberrant Mitochondrial Properties and Function

(A) Reduced gene expression of genes encoded from both the light and heavy chains of the mitochondrial genome in RB1-null hESCs. Two independent control cell lines and three mutant ones are shown.

(B) Quantification of mitochondrial DNA to nuclear DNA (mtDNA/ncDNA) ratio revealed a 45% ± 8% depletion of mtDNA in RB1−/− clones. Two independent control cell lines and three mutant ones are shown.

(C) Oxygen consumption rate (OCR) in control and RB1−/− cells following exposure to different mitochondrial stressors. Data were normalized per 10^4 cells (three independent control cell lines and three mutant ones are shown). Basal respiration was measured for 20 min, followed by oligomycin injection. At 60 min FCCP was injected, revealing significant differences in maximal respiratory capacity between control and RB1-null cells. Antimycin A and rotenone were injected after 80 min. Spare capacity of oxygen consumption was calculated as the difference between basal and maximal OCR. Extracellular acidification rate (ECAR), an indicator for lactate production and glycolysis, was measured for 30 min alongside basal respiration, showing a significant upregulation of glycolysis in mutant cells. FCCP, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; AMY-A, antimycin A.

(D) Representative TEM micrographs of aberrant mitochondria in RB1−/− hESCs (white arrows). Scale bars represent 1 μm.

(E) Quantification of mitochondrial aberration visualized using TEM micrographs in control and RB1−/− hESCs. Percentage of phenotypes observed out of 50 mitochondria in each cell line. Statistical tests were performed with three independent experiments. Error bars represent SEM. *p < 0.05, ***p < 0.001 (calculated using Student’s t test). See also Figure S2.
Figure 3. Analysis of RB1−/− hESC-Derived Teratomas
(A) RB1−/− hESC generate substantially larger teratomas than control cells (n = 4 control tumors, n = 12 mutant tumors). The white arrow points to a representative control teratoma.
(B) Serial sectioning and H&E staining of teratomas reveal enlarged neural structures (black arrows) in RB1−/−-derived teratomas only. Scale bars represent 10 μm.
(C) Immunofluorescence staining of neural cell adhesion molecule 1 (NCAM1) (white arrows) and DAPI in control and RB1−/− teratomas. Scale bars represent 2 mm.
(D) Gene set enrichment analysis of genes up- and downregulated in RB1−/− teratomas.
(E) Significant enrichment for regulation by zinc finger E-box binding homeobox 1 (ZEB1) in genes up- and downregulated in RB1−/− teratomas.
(F) Relative mRNA expression of ZEB1 in control (black) and RB1−/− teratomas (dark red).
(G) Relative mRNA expression of epithelial-mesenchymal transition markers in control (black) and RB1−/− teratomas (dark red).
(H) Relative mRNA expression of keratins suggested to be regulated by ZEB1 in control (black) and RB1−/− teratomas (dark red).
(I) Relative mRNA expression of neural markers suggested to be regulated by ZEB1 in control (black) and RB1−/− teratomas (dark red).
(FDA) was performed on a control and RB1-null cell line, with viability assessment 24, 48, and 72 hr after exposure (Figure 4A). A primary analysis was used to identify significant differential effects between the cell lines, and the effect of 12 of the chemotherapies was then analyzed on additional control and mutant cell lines (Figure 4A). The screening revealed carboplatin as a potent chemotherapy with a significant and consistent differential effect, under which the RB1+/− cells showed an elevated sensitivity (Figures 4B and 4C). Several chemotherapies, including carboplatin, are currently used to treat retinoblastoma, but none of the other chemotherapies showed such a specific effect on RB1-null cells (Figures 4B and 4C). Previous reports suggested that platinum-based chemotherapies similar to carboplatin could affect cells through mitochondrial reactive oxygen species (ROS) response (Marullo et al., 2013). Fluorescence-activated cell sorting of cells stained with mitochondrial superoxide indicator following 24 hr of exposure to carboplatin revealed that RB1+/− cells had significantly elevated basal levels of ROS compared with control cells (Figure 4D). Consequently, exposure to carboplatin drives ROS levels in RB1−/− cells dramatically higher, thus suggesting that carboplatin’s specific effect on RB1−/− cells could originate from their deficient mitochondria. Together, these results demonstrate the potential of our model for identifying compounds specifically targeting RB1-null cells.

**DISCUSSION**

hESCs provide an extraordinary platform for disease modeling, especially for developmental disorders (Avior et al., 2016). We decided to use their unique characteristics to model developmental and tumorigenic aspects of pRB and Trb, a severe neonatal malignancy. Using gene editing, we generated heterozygous and homozygous RB1 mutant hESCs (Figures 1A and S1). Although biallelic inactivation of RB1 is believed to be embryonic lethal, RB1-null hESCs survive and proliferate normally in culture. These observations are similar to those provided by mouse models of retinoblastoma (Jacks et al., 1992). The ability of the cells to perform a normal cell cycle may originate from a functional redundancy of pRB homologous proteins, p107 and p130, encoded by the retinoblastoma-like 1 and 2 (RBL1/2) genes, respectively (Mulligan and Jacks, 1998). Indeed, RB1−/− cells showed a significant upregulation of RBL1 expression (Figure 1C). Although such an attempt might be sufficient to maintain a normal cell cycle (Figures S1D and S1E), we found that the expression of pRB cofactors and targets is altered in RB1-null hESCs (Figure 1D). pRB cofactor upregulation following pRB ablation could be explained by allowing an autoregulation through positive feedback loops, as shown for E2F family members and TBX22 (Andreou et al., 2007; Johnson et al., 1994), or by ablating pRB-regulated degradation, as shown for E1D1 (Miyake et al., 2000). As many pRB cofactors are transcription factors, the downstream effect of their upregulation is alterations in RB1 target expression (Figure 1D).

The most substantial difference between control and RB1−/− hESCs resided in their mitochondrial properties. Mutant cells expressed lower levels of mitochondrially transcribed RNA, with a lower mtDNA copy number and a significantly aberrant mitochondrial function (Figures 2 and S2). The latter included a dramatic reduction in oxidative phosphorylation alongside an increased glycolytic rate and elevated basal levels of ROS (Figures 2C and 4D). Proliferation rate in mutant cells did not change despite the decrease in mitochondrial ATP production, probably due to an adequate compensatory increase in glycolytic ATP generation (Figures 2C and S1E). It is noteworthy that MYC, an E2F-pRB target upregulated in mutant cells (Figure 1D), was suggested to take part in glycolysis upregulation in naïve pluripotent cells (Gu et al., 2016), and therefore could influence the observed phenotype. TEM micrographs revealed that many of the mitochondria in RB1−/− cells were aberrant, being either elongated, deformed, or undergoing autophagy (ghost mitochondria) (Carta et al., 2000) (Figure 2D). Similar phenotypes were recently shown to characterize poorly differentiated retinoblastoma tumor cells (Singh et al., 2016a). It is currently unknown whether these phenomena are a direct result of RB1 biallelic inactivation. However, there have been reports of pRB localizing to the mitochondria (Ferecatu et al., 2009) and directly affecting mitochondrial-mediated apoptosis (Hilgendorf et al., 2013), perhaps mediating mitochondria biogenesis and function. Together, these data suggest the RB1−/− hESCs have cellular characteristics in common with retinoblastoma tumors, contributing to their use as a disease model and in drug discovery.

Utilizing hESC capabilities to differentiate toward the three embryonic germ layers, we used RB1-null hESCs to generate teratomas. These heterogeneous tumors are...
Figure 4. Differential Effects of Chemotherapies on RB1<sup>−/−</sup> Cells

(A) Schematic of experiment. A total of 119 FDA-approved chemotherapies were screened on control and RB1<sup>−/−</sup> cells, with viability evaluation after 24, 48, and 72 hr. Twelve compounds showed a statistically significant differential effect, further validated on multiple control and mutant cell lines (n = 3 experimental replicates for both control and mutant cells).

(B) Time-dependent toxicity curves of 20-µM chemotherapies commonly used to treat trilateral retinoblastoma: carboplatin, cisplatin, doxorubicin, etoposide, topotecan, and vincristine, obtained from RB1<sup>−/−</sup> (dark red) and control (black) cells (three experimental replicates for two control cell lines and three mutant ones).

(C) Dose-dependent toxicity curves of the commonly used chemotherapies, etoposide and carboplatin, obtained from RB1<sup>−/−</sup> (dark red) and control (black) cells (three experimental replicates for two control cell lines and three mutant ones).

(D) Relative levels of mitochondrial reactive oxygen species (ROS) prior and following 24-hr exposure to 10 µM carboplatin (four experimental replicates for control, three experimental replicates for RB1<sup>−/−</sup>). RB1<sup>−/−</sup> cells have significantly higher basal levels of ROS, which are significantly increased following exposure to the chemotherapy. Statistical tests were performed with three independent experiments in triplicates. Error bars represent SEM. *p < 0.02, ***p < 0.001 (calculated using Student’s t test).
Figure 5. A Suggested Model for Effects of RB1 Ablation on Ectodermal Differentiation and Cell Proliferation through ZEB1

Schematic model of ZEB1-mediated effects of RB1 ablation on human development. Following RB1 inactivation E2F upregulates ZEB1 transcription, which in turn promotes epithelial to mesenchymal transition, causing an upregulation of neural differentiation and downregulation of keratin expression. Furthermore, ZEB1 is known to promote cell proliferation through downregulation of microRNA.

indicative of hESC tumorigenic potential and shed light on embryonic developmental processes (Avior et al., 2015; Ozolek and Castro, 2011). RB1-null cells generated significantly larger teratomas, suggesting that RB1 inactivation can enhance cell proliferation alongside differentiation. Histologically, RB1−/− teratomas had a dramatic enhancement of neural structures (Figures 3B and 3C). The neural nature of the tumors echoes the neural component of TRb malignancy, strengthening the validity of our model.

Global gene expression of RB1-null teratomas revealed an upregulation of neural-related genes and a depleted expression of epidermal tissue-related genes. As both the nervous system and the epidermis originate from the ectoderm, these results suggest that the RB1 ablation could alter early ectodermal differentiation cues. The specification between ectodermal fates occurs during early gastrulation, whereby the ventral side of the ectoderm gives rise to epidermal progenitors and the dorsal side to neural progenitors. This developmental process is mediated by repeated and extensive EMT (Duband, 2010). Genes altered in RB1-null teratomas were enriched for genes regulated by ZEB1, a master regulator of EMT (Figure 3E). As ZEB1 expression is suppressed by pRB-E2F1 complex (Liu et al., 2007), inactivation of pRB promotes its expression, leading to repression of E-cadherin (Peinado et al., 2007) and a subsequent repression of epidermal markers such as keratins (Figures 3G, 3H, and 5). ZEB1 was also shown to play a key role in nervous system development in vivo (Liu et al., 2008; Singh et al., 2016b), mirrored in our model by an upregulation of its neural-related targets (Figure 3I). Together, these data provide a plausible model for the shift between two ectodermal derivatives (Figure 5). ZEB1 may also promote teratoma enlargement, as it was found to enhance proliferation (Wellner et al., 2009) and specifically regulate neural proliferation genes such as OLG2 and SOX2 through microRNA repression (Siebzehnrubl et al., 2013; Wellner et al., 2009) (Figures 3J and 5). These observations are also supported by the colocalization of ZEB1 to the neural expansions in RB1-null derived teratomas (Figure 3K).

Together, our data suggest that RB1 developmental and tumorigenic roles could be partially mediated by ZEB1 upregulation. Although more research is required to address these findings in vivo, it can be postulated that the embryonic lethality of RB1 biallelic inactivation in humans originates in part from aberrant ectodermal development mediated by ZEB1.

The similarities between our model and TRb phenotypes in vivo encouraged us to use it as a drug-screening platform. While retinoblastoma is now considered a highly curable disease, TRb is responsible for more than 50% of retinoblastoma-related mortality in the United States (Broad dus et al., 2009). Chemotherapy is the preferred treatment for TRb, surpassing surgery and radiotherapy (de Jong et al., 2015), and in some cases it was enough to eradicate its symptoms (Dunkel et al., 2010; Wright et al., 2010). However, TRb remains a major challenge, with only 44%–57% 5-year survival (de Jong et al., 2015). As the effects of different chemotherapies on retinoblastoma patients vary (Lumbroso-Le Rouic et al., 2016), it is crucial to identify drugs that specifically target cells lacking RB1. hESCs were previously used as a platform for drug screening and discovery, facilitating a rapid transition from the bench side to the clinic (Avior et al., 2016). We tested the effects of 119 FDA-approved chemotherapies on RB1−/− and control cells (Figure 4A). Most of the chemotherapies, including the ones currently used to treat TRb such as etoposide and vincristine (Dunkel et al., 2010), similarly affected control and mutant cells (Figures 4B and 4C). In contrast, carboplatin, an organoplatinum compound that inhibits DNA synthesis, showed a significant, concentration-independent differential effect on RB1-null cells (Figure 4C). This observation of specificity is echoed in the use of carboplatin in the clinic, where it was shown to have a specific effect on retinoblastoma tumor tissues when injected into affected eyes of retinoblastoma patients, with minor effects on healthy surrounding tissues (Leng et al., 2010).

RB1−/− cells exhibited elevated basal levels of mitochondrial ROS compared with control cells (Figure 4D). These levels were induced in control cells following 24-hr exposure to carboplatin, while the same treatment resulted in an additional 40% increase in mitochondrial ROS levels.
in RB1 mutants (Figure 4D). Together with the mitochondrial malfunction and reduced mtDNA abundance in RB1+/− cells, our data suggest that RB1-null cells are more sensitive to carboplatin, potentially due to induced mitochondrial burden. Noticeably, the older organoplatinum chemotherapy cisplatin did not show a differential effect between control and mutant cells (Figure 4B). This can be attributed to cisplatin's elevated toxicity compared with carboplatin, rapidly eliminating all cells (Ozols et al., 2003).

It is important to note that although RB1 inactivation is unique to retinoblastoma initiation, it is functionally inactivated in most human neoplasms (Weinberg, 1995); therefore, utilizing RB1-mutant cells as a drug screen platform could benefit other malignancies as well. In conclusion, we have generated a model for TRb, a tumor-involved developmental disease, using hESCs. Undifferentiated RB1+/− hESCs recapitulate aspects of tumors cells, and mutant cell-derived teratomas resemble TRb tumor composition. Our model sheds light on developmental roles of RB1 as well as on its tumorigenic effects, and can be exploited for future drug discovery.

**EXPERIMENTAL PROCEDURES**

**Cell Culture**
CSES7 and CSES9 hESCs (Biancotti et al., 2010) and their derivatives were cultured using standard conditions as previously described (Mayshar et al., 2010). See also Supplemental Experimental Procedures.

**CRISPR/Cas9 Transfection and Colony Analysis**
RB1 first exon sequence was obtained from the USCS Genome Browser, human genome version GRCh38/hg38. Using the Zhang laboratory online resource (http://crispr.mit.edu/) (Ran et al., 2013), two guide sequences targeting this exon were generated. Guide-carrying plasmids were created as previously described (Ran et al., 2013) using Cas9-puromycin selection plasmid (pSPCas9(BB)-2A-Puro (PX459), Addgene). See also Supplemental Experimental Procedures.

**Western Blot Analysis**
Western blot was performed according to standard protocols. See also Supplemental Experimental Procedures.

**Karyotyping**
Karyotyping was performed according to standard protocols. See also Supplemental Experimental Procedures.

**Nucleic Acid Isolation**
RNA was isolated using NucleoSpin RNA Plus (Macherey-Nagel) according to the manufacturer's instructions. DNA was isolated using a GenElute mammalian genomic DNA miniprep kit (Sigma-Aldrich) according to the manufacturer's instructions. See also Supplemental Experimental Procedures.

**RNA-Seq Expression Data Production, Processing, and Analysis**
Total RNA samples (200 ng to 1 µg, RNA integrity number [RIN] >9) were enriched for mRNAs by pull-down of poly(A)+ RNA. RNA-seq libraries were prepared using the TruSeq RNA Library Prep Kit v2 (Illumina) according to the manufacturer's protocol and sequenced using Illumina NextSeq 500 to generate 85-bp single-end reads. Raw sequencing data were extracted to FASTQ files using SRA-Tools. For a description of processing and analysis, see Supplemental Experimental Procedures.

**Growth Rate Cell-Cycle Analysis**
Cell growth was measured by relative cell viability 24, 48, and 72 hr after equal plating using CellTiter-Glo Luminescent Cell Viability Assay (Promega), according to the manufacturer's instructions. Cell-cycle stage was evaluated by DNA staining using propidium iodide on methanol-fixed and RNase-treated cells, followed by cell sorting using a BD FACSAria III (BD Biosciences).

**mtDNA Quantification**
Mitochondrial to nuclear DNA quantification ratio was analyzed by qPCR based on a previously described method (Xing et al., 2008). In brief, mitochondrial gene MFND2 abundance (forward primer: 5'-TGT TGG TTA TAC CCT TCC CGT ACT A-3'; reverse primer: 5'-CCT GCA AAG ATG GTA GAG TAG ATG A-3') was normalized to the abundance of the nuclear gene BCNJ1 (forward primer: 5'-CCC TCA TCA CAG GGC TCT CTC CA-3'; reverse primer: 5'-GGG ACT GTA GGC TGG GAA CTA TGC-3'). Analysis was performed using the CFX96 qPCR system (Bio-Rad) with KAPA SYBE FAST Universal 2× qPCR Master (KAPA Biosystems).

**Oxygen Consumption Measurement and Mitochondrial Function Assessment**
A Seahorse XFp analyzer (Seahorse Bioscience) was used to measure the oxygen consumption rate (OCR) of undifferentiated hESCs, according to the manufacturer's protocol. See also Supplemental Experimental Procedures.

**Transmission Electron Microscopy Imaging and Quantification**
TEM imaging and quantification were performed according to standard protocols. See also Supplemental Experimental Procedures.

**Neural Progenitor Cell Differentiation**
Differentiation was performed as previously described (Kim et al., 2010). Differentiated Neural progenitor cells were stained with NCAM1 antibody (R&D Systems) and sorted by fluorescence-activated cell sorting using a BD FACSAria III (BD Biosciences).

**Teratoma Formation and Analysis**
All experimental procedures in animals were approved by the ethics committee of the Hebrew University. Undifferentiated hESC colonies were trypsinized into single cells. Cells (~2 × 10⁶) were resuspended in a mixture of 100 µL of Matrigel (Corning) and 100 µL of PBS and injected subcutaneously into a NOD-SCID...
mouse. Exactly 8 weeks post injection, mice were euthanized, and resulting teratomas were extracted, weighed, and dissected. Tumors were dissected into smaller pieces from different areas. Half of the tumor was frozen and saved for H&E staining, performed as previously described (Kopper et al., 2010), while the rest was kept for RNA isolation.

**Immunofluorescence Staining**

Cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) for 15 min at room temperature. Two 5-min PBS washes were performed to remove fixation solution. Cells were then permeabilized in blocking buffer (2% BSA in PBS + 0.25% Triton X-100) for 1 hr at room temperature. Blocking buffer was then drained and replaced with blocking buffer supplemented with primary antibodies (mouse anti-NCAM [304605, BioLegend] or goat anti-ZEB1 [sc-10570, Santa Cruz Biotechnology]), diluted 1:200. Following 1 hr at room temperature, cells were washed three times in PBS for 5 min. Secondary antibodies (Cy2 or Cy3 donkey anti-goat [Jackson ImmunoResearch Laboratories]), diluted 1:200 in blocking buffer, were then added and incubated for 1 hr at room temperature. Hoechst staining was performed using bisBenzimide H33342 trihydrochloride (Sigma-Aldrich) diluted 1:10,000 in PBS, for 2 min. Sections were visualized using an Olympus IX81 microscope.

**Chemotherapy Drug Screening**

Drug toxicity evaluation was based on a previously described method (Ben-David et al., 2014), with slight modifications. See also Supplemental Experimental Procedures.

**Mitochondrial ROS Evaluation**

hESCs were seeded at a density of 7.5 × 10^5 cells per well on a 1 μL/cm² Matrigel-coated 6-well plate. Twenty-four hours after seeding, medium was changed and half of the wells were exposed to 10 μM carboplatin. Twenty-four hours later, mitochondrial ROS evaluation was performed using MitoSOX (Thermo Fisher Scientific) as previously described (Li et al., 2011). In brief, cells were incubated with 3 μM MitoSOX for 10 min, trypsinized, and fixed with 2% paraformaldehyde. Fixed cells were filtered through a 70-μm cell strainer (Corning) and analyzed with a BD FACSAria III (BD Biosciences).

**ACCESSION NUMBERS**

Original RNA-seq data are accessible at the NCBI GEO database under the accession number GEO: GSE84504.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures and three figures and can be found with this article online at http://dx.doi.org/10.1016/j.stemcr.2017.03.005.

**AUTHOR CONTRIBUTIONS**

Y.A. and N.B. conceived the study and wrote the manuscript. Y.A. performed all of the experiments and analyzed the data. E.L. assisted in teratoma analysis and staining. D.Y. was involved in the chemotherapy drug screening and its subsequent analysis. N.B. supervised the study and secured funding.

**ACKNOWLEDGMENTS**

The authors would like to thank Gahl Levy for his help in mitochondria-related assays, Dr. Yael Friedman and Chava Gliksm from the Bio-Imaging unit for their work with the transmission electron microscope, and Prof. Eran Meshorer for critically reading the manuscript. Y.A. is a Clore Fellow. N.B. is the Herbert Cohn Chair in Cancer Research. This work was partially supported by the Israel Science Foundation (grant number 269/12), by The Rossetees Trust, and by The Azrieli Foundation.

Received: October 31, 2016
Accepted: March 7, 2017
Published: April 6, 2017

**REFERENCES**

Andreu, A.M., Pauws, E., Jones, M.C., Singh, M.K., Bussen, M., Douderney, K., Moore, G.E., Kispert, A., Brosens, J.J., and Stanier, P. (2007). TBX22 missense mutations found in patients with X-linked cleft palate affect DNA binding, sumoylation, and transcriptional repression. Am. J. Hum. Genet. 81, 700–712.

Andrusiak, M.G., McClellan, K.A., Dugal-Tessier, D., Julian, L.M., Rodrigues, S.P., Park, D.S., Kennedy, T.E., and Slack, R.S. (2011). Rb/E2F regulates expression of neogenin during neuronal migration. Mol. Cell. Biol. 31, 238–247.

Avior, Y., Biancotti, J.C.C., and Benvenisty, N. (2015). TeratoScore: assessing the differentiation potential of human pluripotent stem cells by quantitative expression analysis of teratomas. Stem Cell Rep. 4, 967–974.

Avior, Y., Sagi, I., and Benvenisty, N. (2016). Pluripotent stem cells in disease modelling and drug discovery. Nat. Rev. Mol. Cell Biol. 17, 170–182.

Ben-David, U., and Benvenisty, N. (2011). The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat. Rev. Cancer 11, 268–277.

Ben-David, U., Arad, G., Weissbein, U., Mandefro, B., Maimon, A., Golan-Lev, T., Narwani, K., Clark, A.T., Andrews, P.W., Benvenisty, N., and Carlos Biancotti, J. (2014). Aneuploidy induces profound changes in gene expression, proliferation and tumorigenicity of human pluripotent stem cells. Nat. Commun. 5, 4825.

Benavente, C.A., and Dyer, M.A. (2015). Genetics and epigenetics of human retinoblastoma. Annu. Rev. Pathol. 10, 547–562.

Biancotti, J.-C., Narwani, K., Buehler, N., Mandefro, B., Golan-Lev, T., Yanuka, O., Clark, A., Hill, D., Benvenisty, N., and Lavon, N. (2010). Human embryonic stem cells as models for aneuploid chromosomal syndromes. Stem Cells 28, 1530–1540.

Broadus, E., Topham, A., and Singh, A.D. (2009). Survival with retinoblastoma in the USA: 1975-2004. Br. J. Ophthalmol. 93, 24–27.

Burkhart, D.L., and Sage, J. (2008). Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer 8, 671–682.
Calo, E., Quintero-Estades, J.A., Danielian, P.S., Nedelcu, S., Berman, S.D., and Lees, J.A. (2010). Rb regulates fate choice and lineage commitment in vivo. Nature 466, 1110–1114.

Carta, A., D’Adda, T., Carrara, F., and Zeviani, M. (2000). Ultrastructural analysis of extraocular muscle in chronic progressive external ophthalmoplegia. Arch. Ophthalmol. 118, 1441–1445.

Classon, M., and Harlow, E. (2002). The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer 2, 910–917.

Conklin, J.F., Baker, J., and Sage, J. (2012). The RB family is required for the self-renewal and survival of human embryonic stem cells. Nat. Commun. 3, 1244.

de Jong, M.C., Kors, W.A., de Graaf, P., Castelijns, J.A., Moll, A.C., and Kivela, T. (2015). The incidence of trilateral retinoblastoma: a systematic review and meta-analysis. Am. J. Ophthalmol. 160, 1116–1126.e5.

Dimaras, H., Kimani, K., Dimba, E.A., Gronsdahl, P., White, A., Chan, H.S., and Gallie, B.L. (2012). Retinoblastoma. Lancet 379, 1436–1446.

Duband, J.L. (2010). Diversity in the molecular and cellular strategies of epithelium-to-mesenchyme transitions: insights from the neural crest. Cell Adh. Migr. 4, 458–482.

Dunkel, I.J., Jubran, R.F., Gururangan, S., Chantada, G.L., Finlay, J.L., Goldman, S., Khakoo, Y., O’Brien, J.M., Orjuela, M., Rodriguez-Galindo, C., et al. (2010). Trilateral retinoblastoma: potentially curable with intensive chemotherapy. Pediatr. Blood Cancer 54, 384–387.

Dynlacht, B.D., Flores, O., Lees, J.A., and Harlow, E. (1994). Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev. 8, 1772–1786.

Dyson, N.J. (2016). RB1: a prototype tumor suppressor and an enigma. Genes Dev. 30, 1492–1502.

Eger, A., Aigner, K., Sonderergger, S., Dampier, B., Oehler, S., Schreiber, M., Berx, G., Cano, A., Beug, H., and Foisner, R. (2005). DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24, 2375–2385.

Ferecatu, I., Le Floch, N., Bergeaud, M., Rodriguez-Enfedaque, A., Rincheval, V., Oliver, L., Vallette, F.M., Mignotte, B., and Vayssière, J.-L. (2009). Evidence for a mitochondrial localization of the retinoblastoma protein. BMC Cell Biol. 10, 50.

Ghanem, N., Andrusiak, M.G., Svoboda, D., Al Lafi, S.M., Julian, L.M., McClellan, K.A., De Repentigny, Y., Kothary, R., Ekker, M., Blais, A., et al. (2012). The Rb/E2F pathway modulates neurogenesis through direct regulation of the Dlx1/Dlx2 bigene cluster. J. Neurosci. 32, 8219–8230.

Goodrich, D.W. (2006). The retinoblastoma tumor-suppressor gene, the exception that proves the rule. Oncogene 25, 5233–5243.

Gu, W., Gaeta, X., Sahakyan, A., Chan, A.B., Hong, C.S., Kim, R., Braas, D., Plath, K., Lowry, W.E., and Christofk, H.R. (2016). Glycolytic metabolism plays a functional role in regulating human pluripotent stem cell state. Cell Stem Cell 19, 476–490.

Hilgendorf, K.L., Leshchiner, E.S., Nedelcu, S., Maynard, M.A., Calo, E., Ianari, A., Walensky, L.D., and Lees, J.A. (2013). The retinoblastoma protein induces apoptosis directly at the mitochondria. Genes Dev. 27, 1003–1015.

Iwanaga, R., Komori, H., Ishida, S., Okamura, N., Nakayama, K., Nakayama, K.I., and Ohtani, K. (2006). Identification of novel E2F1 target genes regulated in cell cycle-dependent and independent manners. Oncogene 25, 1786–1798.

Jacks, T., Fazeli, A., Schmitt, E.M., Bronson, R.T., Goodell, M.A., and Weinberg, R.A. (1992). Effects of an Rb mutation in the mouse. Nature 359, 295–300.

Johnson, D.G., Ohtani, K., and Nevins, J.R. (1994). Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev. 8, 1514–1525.

Kim, D.-S., Lee, J.S., Leem, J.W., Huh, Y.J., Kim, J.Y., Kim, H.-S., Park, I.-H., Daley, G.Q., Hwang, D.-Y., and Kim, D.-W. (2010). Robust enhancement of neural differentiation from human ES and iPS cells regardless of their innate difference in differentiation propensity. Stem Cell Rev. 6, 270–281.

Kivela, T. (2009). The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br. J. Ophthalmol. 93, 1129–1131.

Kopper, O., Giladi, O., Golan-Lev, T., and Benvenisty, N. (2010). Characterization of gastrulation-stage progenitor cells and their inhibitory crosstalk in human embryoid bodies. Stem Cells 28, 75–83.

Koziczak, M., Krek, W., and Nagamine, Y. (2000). Pocket protein-independent repression of urokine-type plasminogen activator and plasminogen activator inhibitor I gene expression by E2F1. Mol. Cell. Biol. 20, 2014–2022.

Leng, T., Cebulla, C.M., Scheffler, A.C., and Murray, T.G. (2010). Focal periocular carboplatin chemotherapy avoids systemic chemotherapy for unilateral, progressive retinoblastoma. Retina 30, S66–S68.

Li, R., Jen, N., Yu, F., and Hsiai, T.K. (2011). Assessing mitochondrial redox status by flow cytometric methods: vascular response to fluid shear stress. Curr. Protoc. Cytom. Chapter 9, Unit9.37.

Liu, Y., Costantino, M.E., Montoya-Durango, D., Higashi, Y., Darling, D.S., and Dean, D.C. (2007). The zinc finger transcription factor ZFHXA1 is linked to cell proliferation by Rb-E2F1. Biochem. J. 408, 79–85.

Liu, Y., El-Naggar, S., Darling, D.S., Higashi, Y., and Dean, D.C. (2008). Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development 135, 579–588.

Lumbroso-Le Rouic, L., Aerts, I., Hajage, D., Lévy-Gabriel, C., Savignoni, A., Algret, N., Cassoux, N., Bertozzi, A.-L., Esteve, M., Doz, F., and Desjardins, L. (2016). Conservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemotherapy-motherapy. Eye (Lond) 30, 46–52.

Manning, A.L., and Dyson, N.J. (2012). RB: mitotic implications of a tumour suppressor. Nat. Rev. Cancer 12, 220–226.

Manning, A.L., Longworth, M.S., and Dyson, N.J. (2010). Loss of pRB causes centromere dysfunction and chromosomal instability. Genes Dev. 24, 1364–1376.

Marullo, R., Werner, E., Degtareva, N., Moore, B., Altavilla, G., Ramalingam, S.S., and Doetsch, P.W. (2013). Cisplatin induces a
mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One 8, e81162.

Mayshar, Y., Ben-David, U., Lavon, N., Biancotti, J.-C., Yakir, B., Clark, A.T., Plath, K., Lowry, W.E., and Benvenisty, N. (2010). Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 7, 521–531.

Merdzhanova, G., Gout, S., Keramidas, M., Edmond, V., Coll, J.L., Brambilla, C., Brambilla, E., Gazzeri, S., and Eymim, B. (2010). The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-

Mulligan, G., and Jacks, T. (1998). The retinoblastoma gene family: Genetic Oncology Group study. J. Clin. Oncol. in patients with optimally resected stage III ovarian cancer: a Gyne- carboplatin and paclitaxel compared with cisplatin and paclitaxel gen, R., and Gynecologic Oncology Group. (2003). Phase III trial of

Moulder, D., Ounap, K., Kaulisch, M., and Lohmann, D. (2011). Genotype-phenotype correlations in patients with retinoblastoma and interstitial 13q deletions. Eur. J. Hum. Genet. 19, 947–958.

Miyake, S., Sellers, W.R., Safran, M., Li, X., Zhao, W., Grossman, S.R., Gan, J., DeCaprio, J.A., Adams, P.D., and Kaelin, W.G. (2000). Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle. Mol. Cell. Biol. 20, 8889–8902.

Mookerjee, S.A., Nicholls, D.G., and Brand, M.D. (2016). Determining maximum glycolytic capacity using extracellular flux measurements. PLoS One 11, e0152016.

Mulligan, G., and Jacks, T. (1998). The retinoblastoma gene family: cousins with overlapping interests. Trends Genet. 14, 223–229.

Ozolek, J.A., and Castro, C.A. (2011). Teratomas derived from embryonic stem cells as models for embryonic development, disease, and tumorigenesis. In Embryonic Stem Cells—Basic Biology and Bioengineering, M. Kallos, ed. (InTech) http://dx.doi.org/10.5772/23866.

Ozols, R.F., Bundy, B.N., Greer, B.E., Fowler, J.M., Clarke-Pearson, D., Burger, R.A., Mannel, R.S., DeGeest, K., Hartenbach, E.M., Baer, gen, R., and Gynecologic Oncology Group. (2003). Phase III trial of

Peinado, H., Olmeda, D., and Cano, A. (2007). Snail, Zeb and bHLH transcription factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7, 415–428.

Prost, S., Lu, P., Caldwell, H., and Harrison, D. (2007). E2F regulates DDB2: consequences for DNA repair in Rb-deficient cells. Oncogene 26, 3572–3581.

Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308.

Richter, S., Vandezande, K., Chen, N., Zhang, K., Sutherland, J., Anderson, J., Han, L., Panton, R., Branco, P., and Gallie, B. (2003). Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am. J. Hum. Genet. 72, 253–269.

Rodjan, F., de Graaf, P., Moll, A.C., Imhof, S.M., Verbeke, J.I.M.L., Sanchez, E., and Casteljins, J.A. (2010). Brain abnormalities on MR imaging in patients with retinoblastoma. AJNR Am. J. Neuroradiol. 31, 1385–1389.

Siebzehnrubl, F.A., Silver, D.J., Tugetitum, B., Deleyrolle, L.P., Sieb- zehnrubl, D., Sarkisian, M.R., Devers, K.G., Yachnis, A.T., Kupper, M.D., Neal, D., et al. (2013). The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol. Med. 5, 1196–1212.

Singh, L., Nag, T.C., and Kashyap, S. (2016a). Ultrastructural changes of mitochondria in human retinoblastoma: correlation with tumor differentiation and invasiveness. Tumor Biol. 37, 5797–5803.

Singh, S., Howell, D., Trivedi, N., Kessler, K., Ong, T., Rosmaninho, P., Raposo, A.A., Robinson, G., Roussel, M.E., Castro, D.S., and Solek, D.J. (2016b). Zeb1 controls neuron differentiation and germinal zone exit by a mesenchymal-epithelial-like transition. Elife 5, e12717.

Stanelle, J., Stiwe, T., Theseling, C.C., Peter, M., and Pützer, B.M. (2002). Gene expression changes in response to E2F1 activation. Nucleic Acids Res. 30, 1859–1867.

Thomas, D.M., Yang, H.-S., Alexander, K., and Hinds, P.W. (2003). Role of the retinoblastoma protein in differentiation and senescence. Cancer Biol. Ther. 2, 124–130.

Vance, K.W., Shaw, H.M., Rodriguez, M., Ott, S., and Goding, C.R. (2010). The retinoblastoma protein modulates Tbx2 functional specificity. Mol. Biol. Cell 21, 2770–2779.

Weinberg, R.A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323–330.

Wellner, U., Schubert, J., Burk, U.C., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., Vannier, C., Darling, D., zur Hausen, A., et al. (2009). The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11, 1487–1495.

Wright, K.D., Qaddouni, I., Patay, Z., Gajjar, A., Wilson, M.W., and Rodriguez-Galindo, C. (2010). Successful treatment of early detected trilateral retinoblastoma using standard infant brain tumor therapy. Pediatr. Blood Cancer 55, 570–572.

Xing, J., Chen, M., Wood, C.G., Lin, J., Spitz, M.R., Ma, J., Amos, C.I., Shields, P.G., Benowitz, N.L., Gu, J., et al. (2008). Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J. Natl. Cancer Inst. 100, 1104–1112.